Literature DB >> 24612196

Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.

Georg Hutarew1, Cornelia Hauser-Kronberger, Felix Strasser, Ida C Llenos, Otto Dietze.   

Abstract

AIMS: ALK FISH analysis is used as the reference standard to demonstrate ALK rearrangements, which qualify patients with pulmonary adenocarcinomas for therapy with ALK inhibitors. The aim of this study was to find screening ALK antibody clones with the best positive and best negative percentage agreement with ALK FISH. METHODS AND
RESULTS: Three hundred and three pulmonary adenocarcinomas were evaluated with ALK FISH and stained with five ALK antibody clones (5A4; D5F3; ALK1; ALK01; SP8) with standardized detection systems. D5F3 was additionally assessed using the OptiView enhanced detection and amplification system. ALK FISH found 14 cases (4.6%) that harboured ALK rearrangements. These stained at all intensities for D5F3 and 5A4. To identify rearranged cases among stained cases, we subsequently analysed all immunohistochemically positive cases with ALK FISH.
CONCLUSIONS: D5F3 with OptiView exclusively stained rearranged cases with strong intensity, without a single false-positive or false-negative case. The number of subsequent ALK FISH analyses required would have decreased from 303 to 14 cases (-95.4%), reducing significantly the time, work and costs without any loss of diagnostic quality and accuracy.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  ALK FISH; ALK antibody clones; ALK mutations in non-small-cell lung cancer; EML4-ALK rearrangement; immunohistochemical screening for ALK rearrangements

Mesh:

Substances:

Year:  2014        PMID: 24612196     DOI: 10.1111/his.12399

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

Authors:  Shuting Ding; Nan Liu; Huanyu Zhao; Guiyang Jiang; Xiupeng Zhang; Enhua Wang
Journal:  Tumour Biol       Date:  2016-02-17

Review 2.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

Authors:  Christine Khoo; Toni-Maree Rogers; Andrew Fellowes; Anthony Bell; Stephen Fox
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 3.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

Review 4.  Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

5.  [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

Authors:  M von Laffert; P Schirmacher; A Warth; W Weichert; R Büttner; R M Huber; J Wolf; F Griesinger; M Dietel; C Grohé
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

Review 6.  Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.

Authors:  Alex Friedlaender; Giuseppe Banna; Sandip Patel; Alfredo Addeo
Journal:  Curr Treat Options Oncol       Date:  2019-09-04

Review 7.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Soft Tissue Tumors.

Authors:  Vickie Y Jo; Elizabeth G Demicco
Journal:  Head Neck Pathol       Date:  2022-03-21

8.  Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Authors:  Todd Hembrough; Wei-Li Liao; Christopher P Hartley; Patrick C Ma; Vamsidhar Velcheti; Christopher Lanigan; Sheeno Thyparambil; Eunkyung An; Manish Monga; David Krizman; Jon Burrows; Laura J Tafe
Journal:  Clin Chem       Date:  2015-11-19       Impact factor: 8.327

9.  Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.

Authors:  Gilles Quéré; Renaud Descourt; Gilles Robinet; Sandrine Autret; Odile Raguenes; Brigitte Fercot; Pierre Alemany; Arnaud Uguen; Claude Férec; Isabelle Quintin-Roué; Gérald Le Gac
Journal:  BMC Cancer       Date:  2016-03-11       Impact factor: 4.430

Review 10.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.